The cannabis market of recent has been full of a large amount of prosperity as new legislation continues to fuel growth throughout the entirety of the space. One of the biggest boosts to the market has been the introduction of new investments from large companies into the cannabis space as well as partnerships in the industry. These have helped to grow the space quite widely over the course of the past few months to a year.
One of the stocks that is at the top of the list and that many have been watching for some time now has been the company Tilray (NASDAQ:TLRY). The company has been one of the major producers of cannabis throughout Canada and has been working to up the production of cannabis for some time now. The company has recently been subject to the massive swings of the market that are associated with any industry in such infancy as cannabis. One analyst stated that “Valuation is complex for Tilray and one needs to fully appreciate the pendulum swinging towards medicinal and recreational use of cannabis globally.” The analyst continued to state that “We have highlighted many positive attributes for Tilray including Privateer Holdings and Leafly, its partnership with Novartis/Sandoz and distribution deals with Shoppers Drug Mart, Pharmasave and others in the pharmacy space and 7 Canadian provinces.” Partnerships like these are continuing to grow the market as a whole and are massively beneficial to companies like Tilray.
The next company on the list, Valens Groworks Corp.’s VGW (CNSX), has been one of the big players in the market in recent times and race qtly received a “Buy” rating from several agencies. The company saw its stock surge by around 47% after the rating was released, but this is purely speculation and the company does have a lot to offer to the market. The company is a specialist in research and production of various cannabis extracts in the industry. According to one report “The company will leverage this opportunity by offering clients proprietary extraction services to produce cannabis oil and derivative products.” Valens remains one stock that investors should continue to watch in the near future.
The last company on the list is one of the smaller guys, but one that has a massive amount of potential in the part of the industry it is in. GT Biopharma Inc (GTBP) has been one of the key players in the biopharmaceutical research and production side of the industry. The biomedical side of the cannabis industry has been one of the fastest growing aspects of the sector for some time now as research continues to show more and more promise for curing and treating various ailments across the board. GT has been working on research using various cannabinoids as the basis for its studies and continues to focus on new types of medicines for the future of medical treatment.
The cannabis industry continues to present itself as one of the most important markets of the modern day. As companies continue to innovate in the space, it is clear that cannabis is here to stay.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
